ABTL0812 (Ibrilatazar)
Metastatic Pancreatic Cancer
Key Facts
About Ability Pharma
Ability Pharma is a Spanish, private biotech founded in 2009, advancing a novel oncology platform based on autophagy-mediated cytotoxicity. Its lead asset, ABTL0812, is a first-in-class oral compound that has completed a Phase 2a trial in endometrial and lung cancers and is currently in a Phase 2b trial for metastatic pancreatic cancer. The company is pre-revenue, has secured strategic investment from SciClone Pharmaceuticals, and is targeting significant unmet needs in oncology with a differentiated mechanism of action.
View full company profileAbout Ability Pharma
Ability Pharma is a Spanish, private biotech founded in 2009, advancing a novel oncology platform based on autophagy-mediated cytotoxicity. Its lead asset, ABTL0812, is a first-in-class oral compound that has completed a Phase 2a trial in endometrial and lung cancers and is currently in a Phase 2b trial for metastatic pancreatic cancer. The company is pre-revenue, has secured strategic investment from SciClone Pharmaceuticals, and is targeting significant unmet needs in oncology with a differentiated mechanism of action.
View full company profileAbout Ability Pharma
Ability Pharma is a Spanish, private biotech founded in 2009, advancing a novel oncology platform based on autophagy-mediated cytotoxicity. Its lead asset, ABTL0812, is a first-in-class oral compound that has completed a Phase 2a trial in endometrial and lung cancers and is currently in a Phase 2b trial for metastatic pancreatic cancer. The company is pre-revenue, has secured strategic investment from SciClone Pharmaceuticals, and is targeting significant unmet needs in oncology with a differentiated mechanism of action.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MesoPher | Amphera | Phase 2 |
| HDM2002 (Mitazalimab) | Huadong Medicine (HD Medicine) | Phase III |